Strategic partnerships Leverage recent collaborations with University of Tennessee, Daisy Genomics, ETHIA, and international partners to position New Day Diagnostics as a collaborative innovator in cancer diagnostics and epigenetic sequencing, creating co-selling and joint go-to-market opportunities.

ColoHealth expansion capitalize on the national and international rollout of ColoHealth for colorectal cancer screening, pursuing hospital systems, clinics, and distributors in regions targeted by SehaMed Global and related Middle East markets to accelerate adoption and reimbursement discussions.

Cancer diagnostics focus Highlight strategic emphasis on colorectal cancer detection and liquid biopsy tools through Daisy Genomics and Colorectal cancer collaborations to create upsell opportunities with existing customers for expanded panels and confirmatory testing.

Licensing and co-development Explore license and co-development deals with Hepion and other partners for in-licensing or co-developing additional diagnostic panels (celiac, respiratory multiplex, H. pylori, HCC) to broaden the product portfolio and cross-sell within existing accounts.

Growth through mid-market focus Target mid-sized hospital labs and regional networks that resemble the profile of Arup, NeoGenomics, and Labcorp in scale but with more agile procurement, offering turnkey screening tests, validation services, and manufacturing partnerships to accelerate adoption and data generation.